Skip to main content

Advertisement

Log in

Economic burden of obesity and its complications in Germany

  • Original Papers
  • Published:
The European Journal of Health Economics, formerly: HEPAC Aims and scope Submit manuscript

Abstract

This study estimated the economic burden of illness of obesity and selected comorbidities in terms of health outcome and costs to society and healthcare payer in Germany. The proportions of selected diseases (comorbidities) attributable solely to obesity were estimated using odds ratios/relative risks and prevalences based on data from the literature. The top-down approach was employed to match healthcare spending with the number of patients suffering from obesity (BMI 30+) and the major comorbidities to evaluate overall direct and indirect costs. In Germany there are approximately 12.24 million obese adults, 2.06–3.76 million of whom suffer from the selected comorbidities. From a societal perspective the total costs for obesity and comorbidities are €2,701–5,682 million per year and the direct treatment costs alone account for €1,343–2,699 million, imposing a major burden to the healthcare system. In view of the magnitude of the economic burden of illness there is a need for both further research and action at the health policy level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Anonymous (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 6 [Suppl 2]:51S–209S

  2. Anonymous (1998) Gesundheitsbericht für Deutschland: Gesundheitsberichterstattung des Bundes/Statistisches Bundesamt. Statistisches Bundesamt. Metzler-Poeschel: Stuttgart

  3. Bergmann KE, Mensink GB (1999) [Anthropometric data and obesity]. Gesundheitswesen 61 [Suppl]:S115–S120

  4. Colditz GA, Willett WC, Rotnitzky A, Manson JE (1995) Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122:481–486

    Google Scholar 

  5. Deutsche Adipositas Gesellschaft (2002) Richtlinien zur Therapie der Adipositas. Deutsche Adipositas Gesellschaft

  6. Hoffmeister H, Horch K (1993) Welche Relevanz hat das Übergewicht für die Gesundheit? Adipositas 5:8–11

    Google Scholar 

  7. Kohlmeier L, Kroke A, Pötzsch J, Kohlmeier M, Martin K (1993) Ernährungsabhängige Krankheiten und ihre Kosten. Nomos: Baden-Baden

  8. Kurscheid T, Lauterbach K (1998) The cost implications of obesity for health care and society. Int J Obes Relat Metab Disord 22 [Suppl 1]:S3–S5

  9. Kübler W (1997) Die nationale Verzehrsstudie (NVS) und die Verbundstudie Ernährungserhebung und Risikofaktoren-Analytik (VERA). VERA-Schriftenreihe, vol XIV. Fleck

  10. Lauterbach K, Westenhöfer J, Wirth A, Hauner H (1998) Adipositas Leitlinie. Evidenz-basierte Leitlinie zur Behandlung der Adipositas in Deutschland.IGKE: Cologne

  11. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al (1990) A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 322:882–889

    Google Scholar 

  12. Okosun IS, Chandra KM, Choi S, Christman J, Dever GE, Prewitt TE (2001) Hypertension and type 2 diabetes comorbidity in adults in the United States: risk of overall and regional adiposity. Obes Res 9:1–9

    Google Scholar 

  13. Quesenberry CP Jr, Caan B, Jacobson A (1998) Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 158:466–472

    Google Scholar 

  14. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, et al (1997) A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 277:1539–1545

    Google Scholar 

  15. Royal College of Physicians (1996) Overweight and obese patients. Principles of management of overweight and obese patients with particular reference to the use of drugs. Royal Coll Physicians

  16. Schneider R (1996) Relevanz und Kosten der Adipositas in Deutschland. Ernährungs-Umschau 43:369–374

  17. Scottish Intercollegiate Guidelines Network (1996) Obesity in Scotland. Integrating prevention with weight management. A national guideline recommended for use in Scotland. SIGN

  18. Seidell JC (1995) The impact of obesity on health status: some implications for health care costs. Int J Obes Relat Metab Disord 19 [Suppl 6]:S13–S16

  19. Statistisches Bundesamt Deutschland (2002) Neue Gesundheitsausgabenrechnung: Gesundheitsausgaben nach Leistungsarten in Mill. EUR. Online Services: 28 May, 21 November

  20. Statistisches Bundesamt Deutschland (2002) Preisindex für die Lebenshaltung (consumer price index). Online Services 27 June

  21. Van Itallie TB (1985) Health implications of overweight and obesity in the United States. Ann Intern Med 103:983–988

    Google Scholar 

  22. Wendland G, Kurscheid T, Lauterbach K (1999) Gesundheitsökonomie und Lebensqualität der S.A.T.-Studie

  23. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al (1995) Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 273:461–465

    Google Scholar 

  24. Wolf AM, Colditz GA (1998) Current estimates of the economic cost of obesity in the United States. Obes Res 6:97–106

    Google Scholar 

Download references

Acknowledgements

We thank Anja Hommel, MSc, and Jens P. Diedrich, PhD, for their contribution to a former version of the manuscript. We are also grateful to Elvira Müller, PhD, for her intellectual contribution and critical reading of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Beate Sander.

Additional information

Financial support for this study was provided entirely by a contract with Abbott GmbH & Co KG, Center for Pharmaceutical Appraisal & Outcomes Research. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

Appendix: calculation of exposure-dependent prevalence

Appendix: calculation of exposure-dependent prevalence

Given:

  • T fields N, e, f, g, h in Table 5

    Table 5. Calculation of exposure-dependent prevalence
  • Odds ratio (OR)

Only one of the fields a, b, c, or d needs to be calculated to estimate all the others:

$$ {OR = odds\;(disease\;\& \;\exp osed)/odds\;(disease\;\& \;non - \exp osed)} $$
$$ OR = {{a/b} \over {c/d}} = {{a*d} \over {b*c}} $$
(1)

Equation 1 needs to be substituted to estimate a:

$$ \matrix{ {a + b = e} & \to & {b = e - a} \cr } $$
(2)
$$ \matrix{ {c + d = f} \hfill & \to \hfill & {d = f - c} \hfill & \to \hfill & {d = f - g + a} \hfill \cr } $$
(3)
$$ \matrix{ {a + c = g} & \to & {c = g - a} \cr } $$
(4)

Substitution of Eq. 1 with Eqs. 2, 3, and 4 leads to:

$$ OR = {{a(f - g + a)} \over {(e - a)*(g - a)}} $$

Rearranging:

$$ OR = {{af - ag + a^2 } \over {eg - ae - ag + a^2 }} $$
$$ {OR = {\left( {a^{2} + (f - g)a} \right)}/{\left( {a^{2} + ( - e - g)a + eg} \right)}} $$
$$ a^2 + (- e - g)a + eg = {\textstyle{1 \over {OR}}}a^2 + {\textstyle{{(f - g)} \over {OR}}}a $$
$$ {{\left( {1 - 1/OR} \right)}a^{2} + {\left[ {{\left( { - e - g} \right)} - (f - g)/OR} \right]}a + eg = 0} $$
$$ \left({1 - {\textstyle{1 \over {OR}}}} \right)a^2 + \left[ {\left({ - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \right]a = - eg $$
$$ a^2 + {{\left[ {\left( { - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \right]} \over {1 - {\textstyle{1 \over {OR}}}}}a = - {{eg} \over {1 - {\textstyle{1 \over {OR}}}}} $$
$$ a^2 + {{\left[ {\left({ - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \right]} \over {1 - {\textstyle{1 \over {OR}}}}}a = - {{eg} \over {1 - {\textstyle{1 \over {OR}}}}} $$ <![CDATA[ $$ a^2 + {{\left[ {\left({ - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \right]} \over {1 - {\textstyle{1 \over {OR}}}}}a + {{eg} \over {1 - {\textstyle{1 \over {OR}}}}} = 0 $$

→ quadratic equation: x 2+px+q=0 where:

$$ x = a $$
(5)
$$ p = {{\left[ {\left({ - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \right]} \over {1 - {\textstyle{1 \over {OR}}}}} $$
(6)
$$ q = {{eg} \over {1 - {\textstyle{1 \over {OR}}}}} $$
(7)

→ solution to quadratic equation: \( x = - {\textstyle{p \over 2}} \pm \sqrt {{\textstyle{{p^2 } \over 4}} - q} \)→ substitute with Eqs. 5, 6, and 7:

$$ a = - {{{{\left[ {\left({ - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \right]} \over {1 - {\textstyle{1 \over {OR}}}}}} \over 2} \pm \sqrt {\left[ {{{\left({{{\left({ - e - g} \right) - {\textstyle{{(f - g)} \over {OR}}}} \over {1 - {\textstyle{1 \over {OR}}}}}} \right)^2 } \over 4}} \right] - \left({{{eg} \over {1 - {\textstyle{1 \over {OR}}}}}} \right)} $$

The attributable proportion in the population (AP pop ) is then calculated by:

$$ AP_{pop} = {{\left[ {\left({{\textstyle{g \over N}}} \right) - \left({{\textstyle{c \over f}}} \right)} \right]} \over {\left({{\textstyle{g \over N}}} \right)}} $$

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sander, B., Bergemann, R. Economic burden of obesity and its complications in Germany. HEPAC 4, 248–253 (2003). https://doi.org/10.1007/s10198-003-0178-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-003-0178-1

Keywords

Navigation